SCHEMBL4135775

SCHEMBL4135775

CCOc1cccc(-c2ccc3c(c2)CCC(N2CCCC2C)C3)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.41
HTR2A P28223 1/20 0.41
HRH3 Q9Y5N1 2/20 0.41
CYP1A2 P05177 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
TMEM97 Q5BJF2 2/20 0.37
SIGMAR1 Q99720 2/20 0.37
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
HIF1A Q16665 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4136724 0.90 HTR2A (0.39) HTR2CHTR2AHRH3CYP1A2CYP11B1
SCHEMBL4136097 0.88 TMEM97 (0.46) HTR2CHRH3CYP11B1CYP11B2ALDH1A1
SCHEMBL4141225 0.88 HRH3 (0.49) HTR2CHRH3TMEM97SIGMAR1GRIN2D
SCHEMBL4133459 0.85 HTR2C (0.44) HTR2CHTR2AHRH3CYP1A2CYP11B1
SCHEMBL4140975 0.84 USP30 (0.45) HRH3CYP11B1CYP11B2TMEM97SIGMAR1
SCHEMBL4129121 0.83 HRH3 (0.39) HRH3CYP1A2CYP11B1CYP11B2TMEM97
SCHEMBL4127461 0.83 HTR2C (0.51) HTR2CHTR2AHRH3CYP1A2CYP11B1
SCHEMBL4142343 0.83 HRH3 (0.40) HRH3CYP1A2CYP11B1CYP11B2GRIN2B
SCHEMBL4141100 0.82 HRH3 (0.38) HRH3CYP1A2CYP11B1CYP11B2SIGMAR1
SCHEMBL4152745 0.82 HRH3 (0.46) HRH3ALDH1A1LMNAHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090163482-A1 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR MCHARDY STANTON FURST 2009-06-25 US claimed
EP-2007749-A2 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR Pfizer Products Inc. (US) 2008-12-31 EP claimed
WO-2007105053-A2 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR PFIZER PRODUCTS INC. (US) 2007-09-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163482-A1 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR HRH3, HRH4, HRH1 HTR2C 9/4885HTR2A 26/4885HRH3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.